Both in Pharmaceuticals
Ultragenyx Pharmaceutical vs Innoviva
Over the past year RARE returned −53.0% and INVA returned +25.8%; their daily moves had a correlation of 0.09.
RARE −53.0% INVA +25.8%Growth of $1, one year, split-adjusted
| Metric | RARE | INVA |
|---|---|---|
| Price | $14.90 | $20.97 |
| Market cap | $1.47B | $1.51B |
| Today | −0.13% | +1.11% |
| 1 month | +14.0% | +0.6% |
| 6 months | −40.8% | −12.3% |
| Year to date | −35.2% | +4.9% |
| 1 year | −53.5% | +23.8% |
| Revenue growth (YoY) | +28.1% | +19.3% |
| Gross margin | 84.1% | 81.3% |
| Net margin | −43.0% | −69.8% |
| P/E (TTM) | — | 4.2× |
| Price / sales | 2.0× | 3.4× |
| Net cash | $292.0M | $319.0M |
| Dividend yield | — | — |
| Volatility (60d) | 127.6% | 22.7% |
| Short % of float | 21.8% | 9.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).